University of Iowa and Feldan Therapeutics awarded grant by the National Institutes of Health Quebec City, Canada, October 12, 2018 – David Guay, Research Director of Feldan Therapeutics (hereafter “Feldan”) announced that his collaborator, Dr. Paul McCray from the University of Iowa Carver College of Medicine (hereafter “UI”), was awarded a $2 million (USD) grant
QUÉBEC CITY, Sept. 18, 2018 /CNW Telbec/ – Feldan Therapeutics (hereafter “Feldan”) has announced the closing of a $12.5 millions Series A financing round led by GC (parent company of GC Pharma), with the participation of Stonebridge Ventures (South Korean-based investor), Anges Québec Capital, including members of Anges Québec, and existing investors. Feldan is focused on the development of
Seoul (South Korea) & Québec City (Canada) June 27, 2018 – GC LabCell (hereafter “GCLC”) and Feldan Therapeutics (hereafter “Feldan”) announced an agreement today granting GCLC exclusive rights to use the Feldan Shuttle platform in developing and manufacturing genetically engineered Natural Killer cells (“NK cells”) for human oncology. GCLC has an international expertise in the
QUEBEC CITY, May 29, 2018 – Feldan Therapeutics, Inc. announced today the issuance of a new patent related to the refinement of the Feldan Shuttle platform. This technology, a peptide-based delivery method which allows the introduction of foreign proteins, peptides or genome-editing nucleases inside cells, is applicable to the development of new therapies. The United States Patent
Feldan Therapeutics’ Research Director, Dr. David Guay, will be attending TIDES: Oligonucleotides and Peptide Therapeutics Conference next week, May 7-10th at Hynes Convention Center in Boston. Come to chat with him and attend to his presentation on May 07th, 3:15 pm to learn more about the development of the Feldan Shuttle technology. https://lifesciences.knect365.com/tides/speakers/david-guay-phd#
QUÉBEC city, March 29, 2018 – CQDM is pleased to announce the selection of a new Quantum Leap project jointly with Feldan Therapeutics for a total amount of $1.2M. The funds will be used for further development of a breakthrough drug delivery technology, in collaboration with Professor Frédéric Calon from Laval University. CQDM’s support for this
Feldan Therapeutics will be attending the Innate Killer Summit from March 27 to 29 in San Diego, CA, USA. Come and meet with our Business Development Director Meriem Benchabane and one of our scientist, Mario Harvey. Discover the Feldan Shuttle, a protein-based technology platform that directly delivers proteins – such as nucleases or transcription factors – inside cells to
- 1
- 2